Car-T Cell Therapy Cost in Malaysia

CAR T cell therapy is a form of cancer immunotherapy that employs T cells, which are immune cells, that have been genetically modified in a lab to improve their ability to detect and eliminate cancer cells. Even when conventional treatments are ineffective, CAR T therapy can be quite effective against specific cancer types. The FDA has currently approved CAR T treatment to treat a number of hematological malignancies, including leukemia, lymphoma, and multiple myeloma. CAR T-cell therapy in Malaysia has shown promising results in the treatment of lymphoma and other blood cancers. Numerous patients with previously relapsed blood tumors have also had positive outcomes, with no sign of malignancy remaining after treatment. Patients who have previously not responded to the majority of conventional cancer treatments now have hope thanks to CAR T-cell therapy.

Chemotherapy and antibody-based therapies are given to patients who have just received a lymphoma diagnosis. CAR-T cell therapy, however, may be an alternative for patients who do not react to two or more lines of such treatment. As a patient’s T-cells, which typically aid in the defense against infections, are gathered and genetically modified to target cancer, receiving CAR-T cell therapy can take a few weeks. The patient receives the modified cells again after low-dose chemotherapy. The lymphoma can then be attacked and eliminated by these cells.

In comparison to the cost of other nations like the United States, United Kingdom, Germany, and others, the cost of  CAR T-cell therapy in Malaysia is much lower.

What Is Car-T Cell Therapy?

T-cells, which have been genetically altered to produce a synthetic T-cell receptor, are used in gene-modified antigen receptor immunotherapy. Chimeric antigen receptors are receptors that have been modified to allow T cells to target a specific antigen. Patients with aggressive relapsed acute lymphoblastic leukemia (ALL) and relapsed non-Hodgkin lymphomas such as Diffused large B-cell lymphoma (DLBCL) respond especially well to CAR T-cell therapy, especially when at least two previous treatment regimens have failed to achieve the desired results.

The Mechanism of Action of Chimeric Antigen Receptor T-Cell Therapy:

1. A patient’s T-cells are taken: T-cells are extracted through the process of apheresis, which involves drawing blood from the body and removing one or more blood components (such as plasma, platelets, or white blood cells). The body is then given the remaining blood.

2. T-cells are genetically modified in a lab: The T-cells are delivered to a lab or a pharmaceutical manufacturing facility, where they are genetically modified by inserting DNA to create chimeric antigen receptors (CARs) on their surface.

3. The T-cells are now referred to as “chimeric antigen receptor (CAR) T cells” as a result of this reengineering: CARs, which are proteins, allow T-cells to recognize an antigen in specific tumor cells.

4. The modified CAR T cells are then multiplied: The quantity of the patient’s genetically altered T-cells is “expanded” by cultivating cells in a lab. Once there is enough CAR – cells, they are frozen and delivered to the medical facility or facility where the patient is being treated.

5. The CAR- T cells are frozen and then administered to the patient at the hospital or treatment facility: Many patients are subjected to a brief course of one or more chemotherapy drugs prior to receiving CAR T-cell infusions, a process known as “lymphodepletion.” The number of reintroduced CAR T-cells in the patient’s bloodstream increases. These are the “attacker” cells, which will detect and attack cells with the specific antigen on their surface.

6. The CAR T-cells could serve as a preventative measure: CAR T-cells, which may remain in the body for months after the infusion, have the potential to eliminate all cancer cells. As a result of the treatment, some types of blood cancer have experienced prolonged remissions.

Who Is the Right Candidate for Car-T Cell Therapy?

Patients from specific patient groups are good candidates for CAR T-cell therapy in Malaysia. They are as follows:

• Patients between the ages of 2 and 25 who have B-cell acute lymphoblastic leukemia (ALL) that is resistant to treatment and who have experienced a relapse later on or after receiving a stem cell transplant.
• Diffuse large B-cell lymphoma (DLBCL) in adults who have not responded to at least two forms of standard therapy.

Patients from the following categories might not be qualified for CAR T-cell therapy:

• Patients who are unconscious or have intracranial hypertension

• Those suffering from respiratory failure

• Those affected by diffuse intravascular coagulation

• Patients with uncontrolled active infections or hematosepsis

Why Is Malaysia a Top Destination for Car-T Cell Therapy?

Malaysia is the ideal destination for medical tourism for a number of reasons. Because it is one of the few in the region where the government actively supports it, the Malaysian medical tourism sector stands out. Visitors are reassured of the industry’s regulations and standards for quality and safety by doing this including those governing medical care.

Malaysia is a popular choice for medical tourism for several reasons, including;

• Accredited hospitals with modern equipment
• Superior health care services
• Affordable rates
• Service and culture
• Geographically well-placed
• Traditional, historical, natural, and tourism destinations

Three important benefits of receiving the best medical treatment in Malaysia are the low cost, high quality of care, and ease of access to top-notch care. Malaysia’s main competitive advantage over other countries is the massive discounts it offers. Several operations are 50% to 70% less expensive than they would be in the EU. Malaysia is perfectly situated, only a few hours by plane from major countries like Indonesia, Brunei, New Zealand, Auckland, and Australia. 

Helpful – Car T-Cell Therapy Cost in India